Public Private Partnerships: Partnerships to accelerate therapy development (Milestone 14.A)
Convene an advisory meeting focused on facilitating public-private partnerships aimed at accelerating the development of effective therapies for AD and ADRD treatment and prevention.
Established working groups on: (i) Rapid Data Sharing and Analysis, (ii) Enabling Bidirectional Translation in AD drug development, (iii) Eliminating IP barriers for Target Validation through clinical proof of concept.
Summary of Key Accomplishments
In April 2013, NIA convened a meeting on enabling partnerships for AD drug development that brought together more than 60 leaders from academia, the NIH, the Foundation for the NIH (FNIH) the FDA, other foundations, public advocacy groups, and the biotech and pharmaceutical industries. The meeting program was developed around key recommendations from the 2012 NIH AD Research Summit. Breakout group discussions centered around new models of data sharing, translational science, and partnering as ways to accelerate AD research and drug development.
This information is current as of March 2022.
- Research Implementation Area
- Public Private Partnerships